Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness. (June 2014)

• Record Type: Journal Article
• Authors: Cheray, Mathilde; Nadaradjane, Arulraj; Bonnet, Pascal; Routier, Sylvain; Vallette, François M; Cartron, Pierre-François
• Is Part Of: Epigenomics. Volume 6:Number 3(2014)
• Page Start: 267
• Page End: 275
• Publication Date: 2014-06
• Subjects: cell death -- DNA methylation -- DNMT1 -- DNMT inhibitor -- epigenetic -- glioblastoma -- glioma; Epigenesis -- Periodicals; Genomics -- Periodicals; Chromatin -- Periodicals; DNA -- Periodicals; 572.87
• DOI: 10.2217/epi.14.18
• Languages: English
• ISSNs: 1750-1911

Abstract

Aim: DNA methylation is a fundamental biologic process of genomes and is a candidate for pharmacological manipulation that might have important therapeutic advantages. Thus, DNA methyltransferases (DNMTs) appear to be ideal targets for drug intervention.Materials & methods: To develop a new generation of DNMT inhibitor, we analyzed the ability of peptides to selectively inhibit certain DNMT1-incuding complexes.Results: Our study demonstrates that the disruption of DNMT1/CFP1-including complexes increases the efficiency of chemotherapeutic treatment on established tumors in mice.Conclusion: Our data opens a promising and innovative alternative to the development of DNMT inhibitors.